Welcome to our dedicated page for Prenetics Global SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prenetics Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prenetics Global's regulatory disclosures and financial reporting.
Prenetics Global Ltd Chief Financial Officer Hoi Chun Lo reported his initial equity holdings. He directly owns 487,462 Class A Ordinary Shares and two groups of Restricted Stock Units that can convert into 15,272 and 32,736 Class A Ordinary Shares at nominal exercise prices, with vesting in 2026 and expirations in 2030 and 2032.
Prenetics Global Ltd director David Vanderveen filed an initial ownership report showing his equity holdings. He directly holds 38,305 Class A Ordinary Shares and an additional 1,648 Class A Ordinary Shares are held indirectly by his spouse. He also holds 8,681 Restricted Stock Units granted under the 2022 Share Incentive Plan, each representing one Class A Ordinary Share. These RSUs vest on June 15, 2026, subject to continued service, and will be settled in shares upon vesting.
Prenetics Global Limited announced that its Board of Directors has authorized a share repurchase program of up to $40 million of its Class A Ordinary Shares over a 12‑month period. This follows open‑market purchases by executives totaling approximately $2.75 million of personal capital across recent post‑earnings trading windows.
The company reports approximately $164 million in total adjusted liquidity as of March 1, 2026 and zero debt, supported by cash, fixed‑income funds, digital assets and divestiture proceeds. Its IM8 brand is targeting $180 million to $200 million in 2026 full‑year revenue and adjusted EBITDA profitability by Q4 2027, and the buyback may be executed via open‑market, block or negotiated purchases, including under Rule 10b5‑1 trading plans.
Prenetics Global Limited reported that its executive leadership team completed a second round of open market purchases of Prenetics common stock during the week of February 23–27, 2026, following the release of its 2025 year-end results. Executives acquired 76,060 shares for an aggregate of about $1,301,000, at an average price of roughly $17.11 per share.
CEO Danny Yeung bought 42,282 shares for approximately $750,000, CFO Stephen Lo bought 15,603 shares for about $250,000, CMO Rahul Ramchand bought 15,000 shares for about $251,000, and President of Americas David Vanderveen bought 3,175 shares for about $50,000. Together with a prior round after the November 2025 earnings release, leadership has now personally invested roughly $2.75 million in Prenetics shares.
The company highlights the growth of its IM8 consumer health brand, which surpassed $100 million in annualized recurring revenue within 11 months and is sold in more than 30 countries.
Prenetics Global Limited reported record 2025 results driven by its IM8 consumer health brand. Full-year revenue jumped to $92.4 million, up 479.7% year over year, with fourth-quarter revenue at $36.6 million, a 457.1% increase, as IM8 became the main growth engine.
IM8 delivered $60.1 million of 2025 revenue and reached about $120 million in annualized recurring revenue by December 2025, with December monthly revenue at $10.0 million and gross margin near 60%. Company-wide adjusted EBITDA loss narrowed to $13.0 million for 2025 and $2.3 million in Q4, showing improving operating leverage despite heavy marketing spend.
Prenetics completed divestitures of ACT Genomics, Europa and its 35% Insighta stake, lifting total adjusted liquidity to $171.1 million as of February 15, 2026, with no debt. Management reaffirmed 2026 IM8 revenue guidance of $180–$200 million and outlined a path toward adjusted EBITDA profitability by the fourth quarter of 2027.
Prenetics Global Limited reports a Board change and a sharpened strategic focus on its IM8 health and longevity brand. Director Andy Cheung resigned effective February 16, 2026, with the company stating his departure was not due to any disagreement. As part of its renewed focus, Prenetics has discontinued any future purchases of Bitcoin or other cryptocurrencies effective December 4, 2025.
The company appointed Dr. Darshan Shah, a longevity expert and health-tech CEO, as an independent director effective February 16, 2026, and he will also serve on key Board committees. Prenetics highlights IM8’s rapid growth, noting the brand surpassed $100 million in annualized recurring revenue within 11 months and is now sold in more than 30 countries.
Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for total cash proceeds of $70 million, providing a substantial, non‑dilutive cash inflow and strengthening its balance sheet.
As of February 15, 2026, Prenetics reported total adjusted liquidity of $171.1 million, including $99.3 million in cash and cash equivalents, $29.3 million in financial assets at fair value through profit or loss, $7.3 million in escrow balances and $35.2 million in Bitcoin, while operating with zero outstanding debt. Management frames this divestiture as the final major step in a strategic shift to focus on IM8, its fast‑growing consumer health and longevity brand, supporting global expansion and product innovation. The company plans to discuss its financial position and outlook with fourth‑quarter and full‑year 2025 results, scheduled for pre‑market release on February 18, 2026.
Prenetics Global Limited submitted a report describing a recent corporate update. On December 30, 2025, the company issued a press release announcing an update to its capital allocation strategy and the cessation of Bitcoin purchases. The report states that this press release is included as an exhibit and is being incorporated by reference into several existing Form F-3 and Form S-8 registration statements, allowing those registration documents to reflect the latest information about the company’s capital allocation approach.
Prenetics Global Limited reports that it will hold its 2025 annual general meeting of shareholders on December 19, 2025. The notice of annual general meeting is furnished as Exhibit 99.1 to this report.
The company also states that this report is incorporated by reference into its existing registration statements on Form F-3 (File Nos. 333-274762, 333-276538 and 333-288824) and Form S-8 (File Nos. 333-279019, 333-271552 and 333-267956), so the information becomes part of those registration statement disclosures.
Prenetics Global Limited submitted a Form 6-K as a foreign private issuer for November 2025. The company reports that on November 24, 2025 it issued a press release announcing open market purchases of its shares by several members of its executive leadership team. The press release describing these executive share purchases is furnished as Exhibit 99.1 to the report.